Evidence Hub

Real-world safety signals of fluoroquinolone-associated peripheral neuropathy: Analysis of US and Canadian databases combined with mechanistic exploration

Guo B, Zou Z, Lu J, Tan S, Mai L

International journal of antimicrobial agents, 2026

6,451 participants

Abstract

Background: The association between fluoroquinolones (FQs) and peripheral neuropathy (PN) poses a severe challenge to patient safety. This study aimed to characterize PN signals for ciprofloxacin, levofloxacin, moxifloxacin, and ofloxacin using large-scale pharmacovigilance databases and explore potential mechanisms.

Methods: Pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS, 2004-2025) were analysed and corroborated with the Canada Vigilance Adverse Reaction Database (CVARD). Signal detection utilized four disproportionality algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayesian geometric mean (EBGM). Time-to-onset, subgroup analysis, and logistic regression were performed on FAERS data to identify clinical patterns. Network toxicology was employed to explore potential mechanisms.

Results: In FAERS (n = 6451), all FQs exhibited significant signals across all four algorithms. In the CVARD validation set, signals were confirmed for ciprofloxacin, levofloxacin, and moxifloxacin, while ofloxacin did not reach significance due to limited data. Within FAERS, ciprofloxacin (OR = 2.71) and levofloxacin (OR = 1.88) exhibited significantly higher reporting odds compared to moxifloxacin (p < 0.001). PN onset was typically rapid (median 4-5 days). Logistic regression identified extended treatment duration and concomitant nitrofurantoin use as important factors…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free